Highly Potent and Subtype-Selective Sperm-Specific Potassium Channel SLO3 Inhibitors Display High Tissue Exposure in...

Area of Science:

• Pharmacology
• Reproductive Biology
• Drug Discovery

Background:

• Drug exposure and distribution in the female reproductive tract are understudied.
• Novel nonhormonal contraceptives are needed.

Purpose of the Study:

• To develop potent and selective sperm-specific potassium channel 3 (SLO3) inhibitors for contraception.
• To evaluate the pharmacokinetic profile and reproductive tract distribution of a lead compound, VU6032735.

Main Methods:

• Extensive in vitro and in vivo drug metabolism and pharmacokinetic studies.
• Selection and characterization of VU6032735 as a tool compound.
• Evaluation of drug exposure and distribution in the female murine reproductive tract over 24 hours post-injection.

Main Results:

• VU6032735 demonstrated low clearance, a long half-life, and high volume of distribution in female mice.
• High tissue exposure of VU6032735 was sustained in the oviduct, the site of fertilization.
• The pharmacokinetic profile suggests suitability for a nonhormonal contraceptive.

Conclusions:

• VU6032735 is a potent and selective SLO3 inhibitor with favorable pharmacokinetic properties for contraceptive development.
• Sustained drug exposure in the oviduct supports its potential as a targeted nonhormonal contraceptive.
• This study establishes a framework for investigating drug disposition in the female reproductive tract.